SCYNEXIS Competitors, Revenue, Alternatives and Pricing

Claim your profile

Overview

Location:
Total Funding:N/A
Industry:Biotech
Founded:2000
Lead Investor(s):N/A

Growjo 10k Ranking

Employee Data

  • SCYNEXIS has 51 Employees.
  • SCYNEXIS grew their employee count by 13% last year.
  • SCYNEXIS currently has 1 job openings.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingPricing
Hydromer
$10.4M67N/AN/AN/A
Cellectar Biosc...
N/A20N/AN/AN/A
Soligenix
N/A28N/AN/AN/A
Gibraltar Labor...
$10.7M69N/AN/AN/A
Apprentice.io
$4.7M30N/AN/AN/A
AES CHEMUNEX
$4M26N/AN/AN/A
GENEWIZ
$91.1M5883%N/AN/A
Amicus Therapeu...
$91.2M555-12%N/AN/A
Celsion Corpora...
N/A40N/AN/AN/A
Hitachi Chemica...
$47.6M30713%N/AN/A
Missing a competitor? Contribute!?
Submit

SCYNEXIS™ provides a full range of synthesis chemistry services to the life sciences industry, From Concept To Clinic™. We offer novel hit generation compounds, hit explosion, lead optimization and radiochemistry services as well as the production of clinical samples in our GMP facility. Every day, SCYNEXIS is demonstrating that our people and technology meet the challenges – and even reshape – today’s pharmaceutical discovery process. The result: our customers are receiving unparalleled speed and efficiency that revolutionize the limits imposed on today’s discovery chemistry lab. SCYNEXIS is increasing the productivity and speed of the pharmaceutical discovery process by removing the boundaries of the chemistry lab. By utilizing our patented MEDCHEM-FACTORY™ process and other proprietary technology platforms, SCYNEXIS is quickly emerging as a company with special expertise in the areas of hit explosion and lead optimization. Harnessing technology in ways never seen before in discovery labs, we are uniquely positioned to meet the specific needs of our customers by providing targeted, and timely, expertise that is tailored to individual projects.

keywords:N/A

51

Number of Employees

N/A

Revenue (est)

1

Current Jobs

13%

Employee Growth %

N/A

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type